Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 1.00 |
| ▸ | MGAM | O43451 | 13/20 | 0.83 |
| ▸ | GAA | P10253 | 13/20 | 0.83 |
| ▸ | SI | P14410 | 13/20 | 0.83 |
| ▸ | MGAM2 | Q2M2H8 | 13/20 | 0.83 |
| ▸ | GUSB | P08236 | 4/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | GFER | P55789 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1670600 | 0.85 | MGAM (0.78) | FAAHMGAMGAASIMGAM2 | |
| SCHEMBL1670602 | 0.85 | MGAM (0.78) | FAAHMGAMGAASIMGAM2 | |
| SCHEMBL4907800 | 0.83 | MGAM (0.81) | FAAHMGAMGAASIMGAM2 | |
| SCHEMBL28590182 | 0.82 | MGAM (0.80) | FAAHMGAMGAASIMGAM2 | |
| SCHEMBL28590184 | 0.82 | MGAM (0.80) | FAAHMGAMGAASIMGAM2 | |
| SCHEMBL30279589 | 0.82 | MGAM (0.80) | FAAHMGAMGAASIMGAM2 | |
| SCHEMBL8791074 | 0.78 | FAAH (0.64) | FAAHMGAMGAASIMGAM2 | |
| SCHEMBL21695177 | 0.78 | GAA (0.64) | FAAHMGAMGAASIMGAM2 | |
| SCHEMBL11607908 | 0.78 | FAAH (0.64) | FAAHMGAMGAASIMGAM2 | |
| SCHEMBL11607906 | 0.78 | FAAH (0.64) | FAAHMGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035932-A1 | NOVEL FORMYL PEPTIDE RECEPTOR LIKE 1 AGONISTS THAT INDUCE MACROPHAGE TUMOR NECROSIS FACTOR ALPHA AND COMPUTATIONAL STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS OF THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-11 | — | — | US | disclosed |
| WO-2002102301-A3 | SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20050120397-A1 | Compounds and methods for regulation of spermatid differentiation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-02 | — | — | US | disclosed |
| US-6747052-B2 | ANTICANCER AGENTS | CYTOVIA, INC. | 2004-06-08 | — | — | US | disclosed |
| US-6747052-B2 | ANTICANCER AGENTS | CYTOVIA, INC. | 2004-06-08 | — | — | US | disclosed |
| US-6747052-B2 | ANTICANCER AGENTS | CYTOVIA, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002102301-A2 | SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002102301-A2 | SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-09-12 | — | — | US | disclosed |
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-09-12 | — | — | US | disclosed |
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | FAAH 588/4885MGAM 4319/4885GAA 3536/4885 |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | FAAH 588/4885MGAM 4319/4885GAA 3536/4885 |
| US-20100035932-A1 | NOVEL FORMYL PEPTIDE RECEPTOR LIKE 1 AGONISTS THAT INDUCE MACROPHAGE TUMOR NECROSIS FACTOR ALPHA AND COMPUTATIONAL STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS OF THEREOF | FPR1, FPR2, FPR3 | FAAH 158/4885MGAM 3612/4885GAA 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.